Solid Biosciences Inc
SLDB6.520USD
+0.290+4.65%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
507.80MMarket Cap
LossP/E TTM
More Details of Solid Biosciences Inc Company
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Solid Biosciences Inc Info
Ticker SymbolSLDB
Company nameSolid Biosciences Inc
IPO dateJan 26, 2018
CEOCumbo (Alexander)
Number of employees100
Security typeOrdinary Share
Fiscal year-endJan 26
Address500 Rutherford Avenue
CityCHARLESTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02129
Phone16173374680
Websitehttps://www.solidbio.com/
Ticker SymbolSLDB
IPO dateJan 26, 2018
CEOCumbo (Alexander)
Company Executives of Solid Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.06K
-80258.00%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
133.53K
+3884.00%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
131.26K
+4573.00%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
116.75K
-37771.00%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
92.38K
-26837.00%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
82.67K
-26535.00%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
71.12K
-26250.00%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+1860.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.06K
-80258.00%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
133.53K
+3884.00%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
131.26K
+4573.00%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
116.75K
-37771.00%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
92.38K
-26837.00%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
82.67K
-26535.00%
Revenue Breakdown
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
Other
52.47%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
Other
52.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.87%
Hedge Fund
23.54%
Investment Advisor/Hedge Fund
18.48%
Private Equity
15.19%
Venture Capital
7.46%
Research Firm
2.38%
Individual Investor
1.13%
Bank and Trust
0.13%
Pension Fund
0.07%
Institutional Shareholding
Updated: Mon, Jan 5
Updated: Mon, Jan 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
257
82.72M
106.17%
-17.41M
2025Q3
245
82.26M
105.58%
-6.26M
2025Q2
237
81.08M
104.59%
+27.37M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
11.83M
15.19%
-73.11K
-0.61%
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.15%
--
--
Sep 30, 2025
Invus Public Equities Advisors, LLC
7.42M
9.52%
--
--
Sep 30, 2025
RA Capital Management, LP
5.81M
7.46%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.06M
5.21%
-309.31K
-7.08%
Sep 30, 2025
Adage Capital Management, L.P.
4.00M
5.13%
-2.73M
-40.56%
Sep 30, 2025
The Vanguard Group, Inc.
3.08M
3.96%
-281.70K
-8.37%
Sep 30, 2025
Vestal Point Capital, LP
2.98M
3.82%
+1.47M
+97.67%
Sep 30, 2025
Fidelity Management & Research Company LLC
2.91M
3.74%
-264.27K
-8.31%
Sep 30, 2025
Citadel Advisors LLC
2.59M
3.33%
+69.40K
+2.75%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.52%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.52%
iShares Micro-Cap ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
